Efficacy and Safety of Ribupatide in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes

Study acronym: KaiNETIC-1
StatusActive, Not Recruiting
PhasePhase 3
SponsorKailera
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Enrollment closed, study ongoing Show 4 more changesShow less
    • Trial sites expanded: 104 → 110 locations
    • Enrollment target: estimated 2340 to confirmed 2530
    • Eligibility criteria expanded, about 16 words
    • Secondary endpoints: details revised at 1 of 30 entries
  2. Trial sites expanded: 88 → 103 locationsv14
  3. Study sites: 88 to 103v13
  4. Enrollment increased: 1800 → 2340 participantsv12 Show 7 more changesShow less
    • Trial sites expanded: 44 → 88 locations
    • Primary completion date: Feb 28, 2028 to Feb 2028
    • Study completion date: Mar 27, 2028 to Mar 2028
    • Interventions: KAI-9531 (Drug), Placebo (Drug) to Placebo (Drug), Ribupatide (Drug)
    • Secondary endpoints revised (30)
    • Study title revised
    • Eligibility criteria expanded, about 3 words
  5. Trial sites expanded: 37 → 44 locationsv11
  6. Study sites: 36 to 37v10
  7. Trial sites expanded: 33 → 36 locationsv9
  8. Trial sites expanded: 30 → 33 locations
    • Trial sites expanded: 22 → 30 locations
    v8
  9. Study sites: 22 to 30v7
  10. Study sites: 20 to 22v6
  11. Study sites: 12 to 20v5
  12. Study sites: 8 to 12v4
  13. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 8
    • Start date changed from estimate of Dec 2025 to Dec 18, 2025
    v3
  14. Re-verified, no change to tracked fieldsv2
  15. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Kailera
7 trials monitored
See all monitored trials
Obesity
3,888 trials monitored
See 157 trials at risk
The primary objective of the study is to determine the effects of ribupatide (KAI-9531) subcutaneous (SC) injection once weekly compared to placebo on percent change in body weight.
Trial Details
NCT Number NCT07284875
Lead Sponsor Kailera
Conditions
(from sponsor)		 Obesity, Overweight
Related terms Obesity, Overweight
Enrollment 2,530 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov